Cargando…

Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer

The goal of this study was to see how effective and safe neoadjuvant chemoradiation with image-guided IMRT was in patients with locally advanced resectable gastric cancer. Between January 2013 and June 2019, patients with locally advanced (cT3/cT4 or N+) gastric cancer treated with neoadjuvant chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jing, Lian, Xin, Guan, Qiu, He, Lei, Zhang, Fuquan, Shen, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600314/
https://www.ncbi.nlm.nih.gov/pubmed/36290863
http://dx.doi.org/10.3390/curroncol29100586
_version_ 1784816811381882880
author Shen, Jing
Lian, Xin
Guan, Qiu
He, Lei
Zhang, Fuquan
Shen, Jie
author_facet Shen, Jing
Lian, Xin
Guan, Qiu
He, Lei
Zhang, Fuquan
Shen, Jie
author_sort Shen, Jing
collection PubMed
description The goal of this study was to see how effective and safe neoadjuvant chemoradiation with image-guided IMRT was in patients with locally advanced resectable gastric cancer. Between January 2013 and June 2019, patients with locally advanced (cT3/cT4 or N+) gastric cancer treated with neoadjuvant chemoradiotherapy at PUMCH (Peking Union Medical College Hospital) were retrospectively studied. Using concurrent chemotherapy (Capecitabine alone or XELOX*2 cycles), radiotherapy (IMRT (intensity-modulated radiation therapy) 45 Gy, 25#, 5 weeks) was delivered with IGRT (image-guided radiotherapy) before the start of each weeks therapy to ensure accuracy and repeatability. A total of 95 patients were enrolled in the study, 93 (97.9%) stage cT3/T4 and 85 (89.5%) stage N+. Of these, 85 patients (89.5%) had a tumor located in the upper 1/3 of the stomach, and 93/95 patients (97.9%) completed neoadjuvant chemoradiation, with 80 patients (84.2%) undergoing stomach resection (58 D2 and 22 D1 gastrostomies). Pathology downstaging was found in 68 patients (85.0%), with 66 patients (82.5%) receiving T downstaging and 56 patients (70.0%) receiving N downstaging. There were 11 individuals (13.8%) who had a pathological complete response (PCR). The average period of follow-up was 44.7 months (19–96 months). The 5-year OS (overall survival), LRFS (local recurrence-free survival), and DMFS (distant metastasis free survival) rates of patients were 47.0% (95% CI: 38.6–55.4), 86.55% (95% CI: 79.1–93.99) and 60.71% (95% CI: 51.49–69.93%), respectively. Thirteen (13.7%) patients had grade 3–4 leukopenia, anemia, and thrombocytopenia, while 9 (9.5%) patients had grade 3–4 anemia, and 5 (5.3%) patients had grade 3–4 thrombocytopenia. PCR was found to be a significant predictive factor for OS in multivariate analysis (HR = 11.211, 95% CI: 1.500–83.813, p = 0.024). The method of using IGRT image-guided IMRT (45 Gy, 25 fractions, 5 weeks) combined with concurrent chemotherapy in patients with locally advanced resectable gastric cancer was equally effective when compared to the clinical efficacy of neoadjuvant chemoradiotherapy, with clinical outcomes achieving equal efficacy, with similar PCR rates and high rates of OS, LRFS, and DMFS, as well as good tolerances of concurrent chemoradiotherapy with acceptable side effects.
format Online
Article
Text
id pubmed-9600314
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96003142022-10-27 Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer Shen, Jing Lian, Xin Guan, Qiu He, Lei Zhang, Fuquan Shen, Jie Curr Oncol Article The goal of this study was to see how effective and safe neoadjuvant chemoradiation with image-guided IMRT was in patients with locally advanced resectable gastric cancer. Between January 2013 and June 2019, patients with locally advanced (cT3/cT4 or N+) gastric cancer treated with neoadjuvant chemoradiotherapy at PUMCH (Peking Union Medical College Hospital) were retrospectively studied. Using concurrent chemotherapy (Capecitabine alone or XELOX*2 cycles), radiotherapy (IMRT (intensity-modulated radiation therapy) 45 Gy, 25#, 5 weeks) was delivered with IGRT (image-guided radiotherapy) before the start of each weeks therapy to ensure accuracy and repeatability. A total of 95 patients were enrolled in the study, 93 (97.9%) stage cT3/T4 and 85 (89.5%) stage N+. Of these, 85 patients (89.5%) had a tumor located in the upper 1/3 of the stomach, and 93/95 patients (97.9%) completed neoadjuvant chemoradiation, with 80 patients (84.2%) undergoing stomach resection (58 D2 and 22 D1 gastrostomies). Pathology downstaging was found in 68 patients (85.0%), with 66 patients (82.5%) receiving T downstaging and 56 patients (70.0%) receiving N downstaging. There were 11 individuals (13.8%) who had a pathological complete response (PCR). The average period of follow-up was 44.7 months (19–96 months). The 5-year OS (overall survival), LRFS (local recurrence-free survival), and DMFS (distant metastasis free survival) rates of patients were 47.0% (95% CI: 38.6–55.4), 86.55% (95% CI: 79.1–93.99) and 60.71% (95% CI: 51.49–69.93%), respectively. Thirteen (13.7%) patients had grade 3–4 leukopenia, anemia, and thrombocytopenia, while 9 (9.5%) patients had grade 3–4 anemia, and 5 (5.3%) patients had grade 3–4 thrombocytopenia. PCR was found to be a significant predictive factor for OS in multivariate analysis (HR = 11.211, 95% CI: 1.500–83.813, p = 0.024). The method of using IGRT image-guided IMRT (45 Gy, 25 fractions, 5 weeks) combined with concurrent chemotherapy in patients with locally advanced resectable gastric cancer was equally effective when compared to the clinical efficacy of neoadjuvant chemoradiotherapy, with clinical outcomes achieving equal efficacy, with similar PCR rates and high rates of OS, LRFS, and DMFS, as well as good tolerances of concurrent chemoradiotherapy with acceptable side effects. MDPI 2022-10-06 /pmc/articles/PMC9600314/ /pubmed/36290863 http://dx.doi.org/10.3390/curroncol29100586 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shen, Jing
Lian, Xin
Guan, Qiu
He, Lei
Zhang, Fuquan
Shen, Jie
Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer
title Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer
title_full Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer
title_fullStr Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer
title_full_unstemmed Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer
title_short Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer
title_sort neoadjuvant chemo-radiation using igrt in patients with locally advanced gastric cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600314/
https://www.ncbi.nlm.nih.gov/pubmed/36290863
http://dx.doi.org/10.3390/curroncol29100586
work_keys_str_mv AT shenjing neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer
AT lianxin neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer
AT guanqiu neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer
AT helei neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer
AT zhangfuquan neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer
AT shenjie neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer